April 22 (Bloomberg) -- Valeant Pharmaceuticals International offered to buy Allergan in a cash-and-stock deal valued at $45.7 billion that will give the Canadian company the Botox wrinkle treatment. Pershing Square Capital Management LP, the fund run by Bill Ackman, Allergan’s largest shareholder, supports the offer, Valeant said. Stephanie Ruhle reports on Bloomberg Television’s “In The Loop.” (Source: Bloomberg)
This text has been automatically generated. It may not be 100% accurate.